Recent Articles from Business Wire

Phillips 66 (NYSE:PSX) (the “Company”) today filed an investor presentation with the U.S. Securities and Exchange Commission in connection with its upcoming Annual Meeting of Shareholders on May 21, 2025.

Today, the U.S. Green Building Council (USGBC) launched LEED v5, the latest version of its flagship LEED (Leadership in Energy and Environmental Design) green building program. LEED v5 builds on the 25-year legacy and global impact of LEED, updating and strengthening the most widely recognized, influential sustainability standard for the building industry while providing user-friendly tools for building owners and teams to pursue certification through enhanced technology updates.

Wayne Wilson, CEO & Founder of SynergenX Health, was named the winner of a Silver Stevie® Award in the Best Entrepreneur - Health Products & Services category in The 23rd Annual American Business Awards®.

Simpson Oil Limited (“Simpson Oil”, “we” or “our”), the largest shareholder of Parkland Corporation (“Parkland” or the “Company”), holding 19.8% of the outstanding common shares, today announced that Glass, Lewis & Co. (“Glass Lewis”), a leading independent proxy advisory firm, has recommended that Parkland shareholders support meaningful boardroom change by voting for seven of its nine director nominees at the Company’s Annual General Meeting (the “Meeting” or the “AGM”) to be held on May 6, 2025.

Americas Gold and Silver Corporation (TSX: USA, NYSE American: USAS) (“Americas” or the “Company”) is pleased to announce that the Company has been included in the Solactive Global Silver Miners Index (“Silver Index”) effective May 1, 2025.

RSA, the security-first identity leader, today announced groundbreaking cybersecurity innovations at RSAC Conference 2025 that defend organizations against the next wave of AI powered identity attacks, including IT Help Desk bypasses, malware, social engineering, and other threats. These advancements are especially critical for organizations implementing passwordless strategies and further solidify RSA's position as the only provider of true, enterprise-ready passwordless identity solutions.

Alliance Resource Partners, L.P. (NASDAQ: ARLP) ("ARLP" or the "Partnership") today reported financial and operating results for the quarter ended March 31, 2025 (the "2025 Quarter"). This release includes comparisons of results to the quarter ended March 31, 2024 (the "2024 Quarter"), and to the quarter ended December 31, 2024 (the "Sequential Quarter"). All references in the text of this release to "net income" refer to "net income attributable to ARLP." For a definition of Adjusted EBITDA and related reconciliation to its comparable GAAP financial measure, please see the end of this release.

While 62 percent of technology and cybersecurity professionals are worried that quantum computing will break today’s internet encryption, only 5 percent say it’s a high priority for the near future, and just 5 percent say their organizations have a defined quantum computing strategy, according to new research from ISACA’s global Quantum Computing Pulse Poll.

Attivare Therapeutics, Inc., an innovative oncology company focused on the development of its ATTimmune biomaterial scaffold cancer therapies to treat patients across a range of solid and liquid tumors with significant unmet medical needs, today announced it will present preclinical data for its novel ATT-01 and ATT-02 therapeutics in two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025.

Celsius Holdings, Inc. (Nasdaq: CELH) today announced that its portfolio brand Alani Nu® surpassed $1 billion in retail sales for the trailing 52-week period ended Apr. 13, 2025, as reported by Circana1. Retail sales increased 72.4% year over year for the same period. This significant milestone has been fueled by accelerated brand growth, strong and unique innovation, and a growing female energy drink consumer segment seeking better-for-you, functional beverages that fit their health and wellness lifestyles.

Anetac, a leader in protecting companies from identity-based vulnerabilities in hybrid environments, today announced the global rollout of Human Link Pro. This powerful new capability unifies the management of human and non-human identity vulnerabilities within the Anetac Identity Vulnerability Management Platform. Already in use by organizations in financial services, retail, healthcare and critical infrastructure, this enhancement addresses the critical need for a single, integrated solution to discover, monitor and respond to vulnerabilities across all identity types–whether employee, non-permanent staff (contractor, partner or supplier) or non-human identities like workloads and service accounts.

Today, Tropical Smoothie Cafe® has announced the 20 inspiring educators who are now finalists vying for the grand prize in the brand’s Sunshine for Teachers contest. Selected from thousands of nominations submitted by consumers nationwide, these finalists are being recognized and rewarded for spreading sunshine in their classroom and community. In May, one grand prize winner will receive a summer getaway worth up to $10,000 and free smoothies for a year.

In a new whitepaper, Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE:TDY), says that emerging cost-effective precision strike solutions that can be safely recovered and reused offer a strong alternative to more commonly deployed ‘One-Way Attack’ or First Person View (FPV) drones.

First Farmers and Merchants Corporation (OTC Pink: FFMH), the holding company for First Farmers and Merchants Bank, today announced its results for the first quarter of 2025.

Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology using next-generation T-cell engagers (TCEs), today announced dosing of the initial patient in the GUARDIAN-101 phase 1 trial of CLSP-1025, the first tumor-specific TCE to enter clinical development. CLSP-1025 exclusively targets cancer cells expressing the p53R175H mutation, a mutation associated with a wide range of solid tumors, including colorectal, pancreatic, lung, gastric, esophageal, gynecological, and prostate cancers.

Graylog, the no-nonsense platform for Security, API protection, and IT Operations, today launched its Spring 2025 release of Graylog Security—pushing further past the limits of traditional SIEM. Building on the Fall 2024 release (version 6.1), Graylog sharpens analyst workflows, accelerates time-to-value, and sets a new bar for speed and flexibility in threat detection.

Ziff Davis, Inc. (NASDAQ: ZD) today announced its participation in one investor conference in May.

H Partners Management, LLC (“H Partners” or “we”), one of the largest shareholders of Harley-Davidson, Inc. (NYSE: HOG) (“Harley-Davidson” or the “Company”), which beneficially owns approximately 9.1% of the outstanding shares of the Company, today announced that it has filed a definitive proxy statement with the U.S. Securities and Exchange Commission in connection with its campaign to urge shareholders to vote “WITHHOLD” on the election of three long-tenured incumbent directors – CEO and Chairman Jochen Zeitz, Presiding Director Thomas Linebarger, and 29-year director Sara Levinson – at the Company’s 2025 Annual Meeting of Shareholders (the “Annual Meeting”) scheduled for May 14, 2025.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) to Merck KGaA, Darmstadt, Germany for $47.00 per share in cash is fair to SpringWorks shareholders.

Ryder System, Inc. (NYSE: R) launches a national television ad campaign, “Stories from the Supply Chain,” showcasing real businesses navigating logistics challenges in an ever-shifting supply chain environment. From fashion to fine wines and spirits, the initial campaign highlights two Ryder customers – Mugsy and Southern Glazer’s Wine & Spirits – candidly recounting the moments they realized it was time to call the supply chain experts.

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, announced today that David Hallal has been appointed Chief Executive Officer succeeding Jay Backstrom, M.D. David Hallal has served as Chairman of the Board at Scholar Rock since 2017 and just prior to that spent more than a decade as CEO, COO, and CCO of Alexion building and leading the company’s 50-country operating platform. As part of this planned transition, Dr. Backstrom will serve as a strategic advisor, working closely with the company’s executive team and Board of Directors.

Rithm Property Trust Inc. (NYSE: RPT, “Rithm Property Trust” or the “Company”) today announced the following information for the quarter ended March 31, 2025.

BankUnited, Inc. (the “Company”) (NYSE: BKU) today announced financial results for the quarter ended March 31, 2025.

Lindsay Corporation (NYSE: LNN), a leading global manufacturer and distributor of irrigation and infrastructure equipment and technology, today announced that Randy Wood, President and Chief Executive Officer, and Brian Ketcham, Senior Vice President and Chief Financial Officer, will present on an investment panel at the Gabelli Funds 16th Annual Value Investor Conference, being held May 2nd at The Hilton Omaha in Omaha, NE.

Hyatt Hotels Corporation (“Hyatt” or the “Company”) (NYSE: H), a leading global hospitality company, announced today that HI Holdings Playa B.V., an indirect wholly owned subsidiary of Hyatt (“Buyer”), has extended the offering period of its previously announced cash tender offer to purchase all of the outstanding ordinary shares of Playa Hotels & Resorts N.V. (“Playa”) (NASDAQ: PLYA) for $13.50 per share in cash, less any applicable withholding taxes and without interest. The offer is being made pursuant to the previously announced purchase agreement, dated February 9, 2025 (the “Purchase Agreement”), among Hyatt, Buyer and Playa.

Perfect Corp. (NYSE: PERF) (“Perfect” or the “Company”), a leading artificial intelligence (“AI”) company offering AI and augmented reality (“AR”) powered solutions to beauty and fashion industries, today announced its unaudited financial results for the three months ended March 31, 2025.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2025, and provide an update on recent developments, on May 8, 2025.

Global IT firm FPT announced its inclusion in Forrester’s The Digital Transformation Services Landscape, Q2 2025. The report provides an overview of 35 digital transformation service providers and offers valuable insights into the current market dynamics.

Walker & Dunlop, Inc. announced today that it has expanded its presence in Texas with a regional CBRE veteran, Mike Bryant. As senior managing director, based in and native to Dallas, Bryant will be responsible for new loan originations, with a focus on multifamily lending through government-sponsored enterprises (GSEs) such as Fannie Mae and Freddie Mac.

Advanced Energy Industries, Inc. (NASDAQ: AEIS), a global leader in highly engineered, precision power conversion, measurement, and control solutions, today announced that its board of directors has authorized a quarterly cash dividend of $0.10 per share, payable on June 6, 2025 to shareholders of record as of May 24, 2025.

Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its Board of Directors has appointed Ashley McEvoy President and Chief Executive Officer and a member of the Board of Directors, effective immediately.

Peridio, the platform for building and maintaining advanced embedded products, today announced Avocado OS, its groundbreaking open-source Embedded Linux distribution designed to reshape the embedded product development lifecycle. Avocado OS delivers a seamless developer while providing robust security, reliability, and deterministic performance essential for complex embedded products.

Abnormal AI, the leader in AI-native human behavior security, today unveiled its most ambitious product release to date—introducing autonomous AI agents that revolutionize how organizations train employees and report on risk, while also evolving its email security capabilities to continue to stop the world’s most advanced email attacks. In a year defined by the explosive use of malicious AI for cybercrime, Abnormal is doubling down on its mission to protect people. With its AI-native platform, Abnormal’s newest innovations bring intelligent automation to security awareness training, executive reporting, and advanced email threat detection.

Cyware, the leader in AI-powered threat intelligence management, intelligence sharing and collaboration, as well as hyper-orchestration and response, has been named the 2025 winner of Security Today’s prestigious GOVIES Award for innovation in AI-driven Cyber Threat Management.

Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 30, 2025.

Konovo, a technology-first healthcare intelligence company, formally launched today with a new mission to simplify and enable research across the insights ecosystem of researchers, vendors and data sources. Building on a long history of success in research under three separate brands, Konovo applies technology to address the industry’s longstanding challenges: fragmentation, isolated learnings, and disengaged responders, all of which cause delays, reduce efficiencies, and affect quality. Fueled by new leadership, vision, and technology investment, Konovo is expanding the industry’s first AI-native, intelligent platform to streamline and accelerate deeper insights – rooted in its track record of award-winning AI innovations pioneered by InCrowd, SHG and GlocalMind.

Experian Health today released its annual 2025 State of Patient Access Survey, which reveals some alignment between patients and providers but also a few areas of polarization. Patient and provider respondents said access “was about the same” at the highest levels since 2022 (68% and 43%, respectively) and fewer patients are saying that access is worse compared to previous years, which may reflect an overall better experience. Among those that say access is better (16%), the top reason is they can see a practitioner quickly. However, the top challenge for patients that say access is worse (15%) remains being able to see a provider quickly while, ironically, the biggest challenge for providers is getting patients to use the digital access services designed to help remedy this issue.

Seasons Federal Credit Union is embracing a bold new chapter, rebranding as Ellafi Federal Credit Union on April 28, 2025. As it celebrates 90 years of service and 20 years as Seasons, the credit union is evolving to better serve its members and community, with a mission centered on financial independence and economic resilience for women and their allies, collectively referred to as women+.

Underoutfit, a fast-growing brand in women’s intimates, is launching its first national linear television campaign this week in partnership with All-Inclusive TV agency Marketing Architects.

Acuity Knowledge Partners (Acuity), a leading provider of bespoke technology, analytics, and research to the financial services sector, is excited to announce the launch of a market leading, deep domain specific Agentic AI platform - Agent Fleet for Banks, Asset Managers, and Private Equity houses.

Continuing an over two decade-long tradition of bringing together employees to volunteer in their local communities, Charles Schwab will again host Schwab Volunteer Week across the country. Taking place April 28-May 9, this year’s event will focus on serving nearly 350 nonprofits across the U.S. through more than 10,000 volunteer opportunities.

Astoriom, a global leader in the R&D sample stability and biorepository storage industry, today announced the appointment of Ryan Smith as Global Head of Sales. He will build on the strong foundation already in place to further scale Astoriom’s portfolio of sample stability storage, biorepository storage, disaster protection and recovery, as well as sample storage equipment and validation services. Ryan’s appointment demonstrates the company’s commitment to its evolving commercial strategy and continued expansion in key markets worldwide, enabling scientists to safeguard the integrity and viability of their valuable sample assets to advance their research.

Metrion Biosciences (“Metrion”), the specialist preclinical contract research organisation (CRO) and a global leader in ion channel services, today announced the launch of its validated, high-throughput NaV1.9 screening assay to advance discovery and development of novel pain therapeutics. Leveraging over a decade of electrophysiology expertise, the NaV1.9 assay, alongside Metrion’s unique combination of ion channel expertise, bespoke assays and pain research services, enables researchers to overcome traditional limitations of NaV1.9 screening and generate reproducible and decision-ready data.

The "Post Event Analysis - Australian Open 2025" report has been added to ResearchAndMarkets.com's offering.

RSA 2025 - CrowdStrike (NASDAQ: CRWD) today unveiled Charlotte AI Agentic Response and Charlotte AI Agentic Workflows, marking a leap forward in modern SOC operations. Combined with the previously announced Charlotte AI Agentic Detection Triage, Charlotte AI transcends “ask-and-respond” copilots, delivering autonomous reasoning and action on first- and third-party data. The AI-native CrowdStrike Falcon® platform is now cybersecurity’s intelligent reasoning AI platform, drawing conclusions without human prompts and taking action with bounded autonomy.

Mitsubishi Electric Corporation (TOKYO: 6503) announced today that the company’s Board of Directors resolved on April 28, 2025 to repurchase shares of the company’s stock, as shown below, pursuant to the provisions of Article 459, paragraph 1 of the Companies Act, as well as Article 31 of the company’s articles of incorporations.

Mitsubishi Electric Corporation (TOKYO: 6503) announced today its consolidated financial results for fiscal 2025 (April 1, 2024 - March 31, 2025).

Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a Stamford, Connecticut-based commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the companies have entered into a definitive agreement for Merck KGaA, Darmstadt, Germany, to acquire SpringWorks. The purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) based on SpringWorks’ cash balance as of December 31, 2024, and a premium of 26% to SpringWorks’ unaffected 20-day volume-weighted average price of $37.38 on February 7, 2025, the day prior to the first market speculation of a potential transaction between Merck KGaA, Darmstadt, Germany, and SpringWorks.

Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS.

Regulatory News:

Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V., a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region.

An innovative bin monitoring system that enables feed mill operators to access real-time bin levels, 24/7, eliminating the need for the hazardous practice of manual bin dropping is launching in the United States.

Swissport International, a leading provider of ground services and cargo handling for the aviation sector, has announced a strategic partnership with global safety and quality software company Ideagen to accelerate their 2030 Vision of Zero Harm. This collaboration will enable Swissport to share information with governing bodies more easily to drive safety compliance.

Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global shared intelligent electric mobility ecosystem company, recently received congratulatory messages and unwavering outpouring of support from California political leaders on the Company’s Bridge Strategy, it’s FX brand and the recent appointment of YT Jia to the position of Co-CEO of the Company. The remarks were made at the Company’s recent ‘FF Stockholder Community and FX Co-Creation Day’ event held at FF’s headquarters in Los Angeles. During the meeting, both government as well as Company leaders gave pertinent updates on FF, the FX brand as well as congratulatory messages on YT’s appointment as Co-CEO. YT also gave a number of new business updates and key transformational aspirations for the Company moving forward.

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Skyworks Solutions, Inc. (NASDAQ: SWKS) between July 30, 2024 and February 5, 2025. Skyworks describes itself as a “developer, manufacturer, and provider of analog and mixed-signal semiconductor products and solutions for numerous applications, including aerospace, automotive, broadband, cellular infrastructure, connected home, defense, entertainment and gaming, industrial, medical, smartphone, tablet, and wearables.”

Valnet Inc. (“Valnet”) and its Co-Founder and CEO, Hassan Youssef, have filed a lawsuit in the United States District Court for the District of Delaware against The Wrap News Inc. (“The Wrap”) for defamation, unfair competition and other illegal actions taken by The Wrap in connection with an article published by The Wrap on March 20, 2025 smearing Valnet and Mr. Youssef.

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights a duration of response of nearly four years from a long-term follow-up study with JELMYTO® (mitomycin) for pyelocalyceal solution, which is FDA-approved for the treatment of low-grade upper tract urothelial cancer (LG-UTUC) in adult patients.

Phixius by Nacha—a secure, peer-to-peer payment information network—announced today that ValidiFI is live on the Phixius network as an additional provider of bank account validation. Phixius now offers multiple providers of account validation, expanding the coverage of account validation data for Phixius users.

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced patient-reported outcomes following treatment of patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) that showed investigational drug UGN-102 (mitomycin) for intravesical solution achieved robust and durable complete response (CR) rates without negatively impacting quality of life. The data (Moderated Poster - MP15) were presented at the AUA 2025 Annual Meeting in Las Vegas, Nevada.

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced new data from the OPTIMA II Phase 2b study of UGN‑102 (mitomycin) for intravesical solution demonstrate clinically meaningful two-year duration of response (24.2 months) by Kaplan-Meier analysis. UGN-102 is UroGen’s sustained-release formulation of mitomycin being developed for the treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers and acquirers of Geron Corporation (NASDAQ: GERN) securities between February 28, 2024 and February 25, 2025. Geron is a commercial-stage biopharmaceutical company.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, as a perioperative treatment regimen for patients with stage III or IVA, resected, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Results at the first interim analysis of the trial showed KEYTRUDA significantly improved event-free survival (EFS) as part of a perioperative treatment regimen with adjuvant standard of care (SOC) radiotherapy with or without cisplatin compared to adjuvant standard of care (SOC) radiotherapy with or without cisplatin alone in patients with resectable LA-HNSCC. These data are being presented for the first time today during a Plenary Session at the American Association for Cancer Research (AACR) Annual Meeting 2025 (Abstract #CT001) and were selected for the AACR press program.

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of common stock of Fluence Energy, Inc. (NASDAQ: FLNC) between November 29, 2023 and February 10, 2025. Fluence describes itself as a company that “offers energy storage products and solutions, delivery services, recurring operational and maintenance services, and digital applications and solutions for energy storage and other power assets.”

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of common stock of Ready Capital Corporation (NYSE: RC) between November 7, 2024 and March 2, 2025. Ready Capital describes itself as a real estate finance company.

The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against Geron Corporation (“Geron”) (NASDAQ: GERN) on behalf of those who purchased or otherwise acquired Geron securities between February 28, 2024, and February 25, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is May 12, 2025.

Swimlane, AI hyperautomation for the entire security organization, today announced it has been named the “Most Valuable Pioneer” in AI maturity by QKS Group. In the 2025 QKS AI Maturity Matrix™, Swimlane ranks ahead of seven other vendors for its AI-first productization, advanced vision and agentic AI roadmap. Swimlane is ranked ahead of Palo Alto Networks, Cisco, D3, Tines, Fortinet, Torq and Anomali.

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI) between August 7, 2024 and February 24, 2025. Maravai is a life sciences company which provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide.

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of TFI International Inc. (NYSE: TFII) between April 26, 2024 and February 19, 2025. TFI International is a transportation and logistics company.

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Rocket Lab USA, Inc. (NASDAQ: RKLB) between November 12, 2024 and February 25, 2025. Rocket Lab describes itself as a “space company which provides launch services, spacecraft design services, spacecraft components, spacecraft manufacturing and other spacecraft and on-orbit management solutions.”

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of e.l.f. Beauty, Inc. (“Elf”) (NYSE: ELF) between November 1, 2023 and November 19, 2024. Elf describes itself as a company that “provides cosmetic and skin care products.”

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Quantum Computing Inc. (NASDAQ: QUBT) between March 30, 2020 and January 15, 2025. Quantum Computing describes itself as an “American company that purportedly utilizes non-linear quantum optics to deliver quantum products for high-performance computing applications.”

Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients.

EyeMD EMR Healthcare Systems, Inc., (“EyeMD EMR” or “the Company”), a leading provider of healthcare technology software solutions purpose-built for ophthalmologists and eye care specialists, announced a significant majority growth investment from Performant Capital, a Chicago-based private equity firm focused on partnering with and scaling software and technology-enabled businesses.

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced an updated 18-month DOR of 80.6% (95% CI: 74.0, 85.7), by Kaplan-Meier estimate, from the Phase 3 ENVISION trial of UGN-102 (mitomycin) for intravesical solution, an investigational treatment for recurrent LG-IR-NMIBC. These data were featured today in an Oral Presentation Session (Abstract ID: PD12) at the AUA 2025 Annual Meeting in Las Vegas, Nevada.

Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with standard of care (SOC) Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The trial met its primary endpoint of event-free survival (EFS) by investigator assessment, demonstrating a clinically meaningful and statistically significant improvement with sasanlimab in combination with BCG (induction and maintenance) as compared to BCG alone (induction and maintenance): Hazard Ratio (HR) of 0.68; 95% Confidence Interval (CI), 0.49-0.94; 2-sided p=0.019; median EFS not yet reached. These findings show a 32% reduction in risk of disease-related events, including high-grade disease recurrence or progression, with the sasanlimab combination regimen as compared with SOC treatment alone. Pre-specified subgroup analyses for patients harboring higher risk disease showed consistent benefit with EFS HR of 0.63 (0.41, 0.96) for T1 disease, and EFS HR 0.53 (0.29, 0.98) for those with CIS disease.